Black Diamond Therapeutics, Inc. (BDTX) NASDAQ
3.34
+0.19(+6.03%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.34
+0.19(+6.03%)
Currency In USD
Address
One Main Street
Cambridge, MA 02142
United States of America (the)
Phone
617 252 0848
Sector
Healthcare
Industry
Biotechnology
Employees
24
First IPO Date
January 31, 2020
| Name | Title | Pay | Year Born |
| Mark A. Velleca | Chief Executive Officer, President & Chairman | 972,842 | 1964 |
| Elizabeth Buck | Co-Founder & Chief Scientific Officer | 340,473 | 1975 |
| Brent Hatzis-Schoch | Chief Operating Officer & General Counsel | 703,735 | 1965 |
| Sergey Yurasov | Chief Medical Officer | 725,969 | 1969 |
| Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller | 0 | 1985 |
| Melanie Morrison | Chief Development Officer | 0 | 1975 |
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.